In biopharma R&D, AI investment has overwhelmingly targeted generating more drug candidates, even though the industry has rarely lacked for compounds worth pursuing. In this episode, Mukhtar Ahmed, Director of Project and Portfolio Strategy at Greenstone Biosciences, explores why the harder and more valuable problem is deciding which candidates deserve continued capital and attention. The conversation covers synthesizing fragmented evidence across teams, keeping human judgment and accountability in the loop, and measuring AI's impact across a portfolio rather than a single program.

​

Emerj works with a select group of AI vendors to reach Fortune 500 decision-makers through research, media, and direct access. If you want to be considered, download our media kit at emerj.com/AD1